Opinion|Videos|November 20, 2026

HER2-Mutant NSCLC: DESTINY-Lung04 and First-Line T-DXd Efficacy

In this segment of the OncLive Peer Exchange®, Dr. Benjamin P. Levy and Dr. Julia Rotow discuss the phase 3 DESTINY-Lung04 trial, which evaluated trastuzumab deruxtecan (T-DXd) against platinum-based chemotherapy in the first-line treatment of HER2-mutant non-small cell lung cancer (NSCLC).

In this segment of the OncLive Peer Exchange®, Dr. Benjamin P. Levy and Dr. Julia Rotow discuss the phase 3 DESTINY-Lung04 trial, which evaluated trastuzumab deruxtecan (T-DXd) against platinum-based chemotherapy in the first-line treatment of HER2-mutant non-small cell lung cancer (NSCLC). Dr. Rotow outlines the randomized trial design, including the comparator regimen and eligibility of patients with stable brain metastases. The panel reviews the key efficacy findings, including improved progression-free survival and a higher objective response rate with T-DXd, approximately 70% versus 40% with chemotherapy. Dr. Narjust Florez highlights the clinical relevance of these response rates, noting that patients with HER2-mutant NSCLC may present with substantial symptom burden, brain metastases, and other disease-related complications. The experts discuss how higher response rates may enable more rapid symptom improvement and meaningful clinical benefit. They also note that overall survival data remain immature, with a final analysis still pending, and begin to consider the trial's CNS outcomes and their implications for treatment selection.


Related to this article